Long-term comparison of everolimus-eluting and biolimus-eluting stents

Puricel, Serban; Oberhänsli, Markus; Guntern, Patricia; Lehmann, Sonja; Goy, Jean‐Jácques; Arroyo, Diego; Villeneuve, Hélène; Baeriswyl, Gérard; Stauffer, Jean‐Christophe; Togni, Mario; Cook, Stéphane

doi:10.4244/eijv9i3a55

Cited by 9 publications

(8 citation statements)

References 23 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Recently, Puricel et al reported that at 2 years the frequency of stent thrombosis after BES implantation is equal to that after EES implantation. 27 According to the Japanese Circulation Society guidelines, DAPT should be taken for at least 1 year. 28 However, recent data have revealed that the incidence of stent thrombosis at 24 months was not different between 6-month and 24-month DAPT groups after second-generation DES implantation.…”

Section: Possibility For Shortening the Duration Of Daptmentioning

confidence: 99%

Favorable Vessel Healing After Nobori Biolimus A9-Eluting Stent Implantation

Konishi

Shinke

Otake

et al. 2014

Circ J

View full text Add to dashboard Cite

Section: Possibility For Shortening the Duration Of Daptmentioning

confidence: 99%

Favorable Vessel Healing After Nobori Biolimus A9-Eluting Stent Implantation

Konishi

Shinke

Otake

et al. 2014

Circ J

View full text Add to dashboard Cite

“…After the establishment of BP-BES's noninferiority to DP-EES in randomized trials, 16,21,22 some recent studies have focused on evaluating the advantages of BP-BES over DP-EES. 11,12 Puricel and colleagues 12 compared clinical outcomes in 200 propensity-score-matched pairs of patients (one treated by EES and the other treated by BES) and reported that, at 24 months after PCI, MACE had occurred in 10.5% of the BP-BES group and in 11.5% of the DP-EES group, with no significant difference. At the one-year follow-up, an analysis of a single-center registry of unrestricted use of EES and Biomatrix BES in 406 propensity-score-matched pairs showed a similar rate of target-lesion failure, stent thrombosis, and patient-oriented composite outcome.…”

Section: Discussionmentioning

confidence: 99%

“…Trials have shown the noninferiority of the biodegradable-polymer biolimus-eluting stent (BP-BES) to the previous generations of DESs; however, only a few investigators have compared the biodegradable-polymer with the durable-polymer DES in real-world registries. 11,12 Further analysis of large and comprehensive data registries seemed to be necessary to compare the efficacy and safety of those stents. During a 12-month follow-up period, we compared the incidence of major adverse cardiac events (MACE) in patients who underwent percutaneous coronary intervention (PCI) with the biodegradable-polymer biolimus-eluting stent (BP-BES) versus the incidence of MACE in patients who underwent PCI with the durable-polymer everolimus-eluting stent (DP-EES).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study

Parsa¹,

Saroukhani²,

Majlessi³

et al. 2016

Texas Heart Institute Journal

View full text Add to dashboard Cite

We compared outcomes of percutaneous coronary intervention patients who received biodegradable-polymer biolimus-eluting stents with those who received durable-polymer everolimus-eluting stents.At C oronary artery stenting is widely accepted as the treatment of choice for most cases of coronary artery disease (CAD). Implantation of the drug-eluting stents (DESs), in comparison with the bare-metal stents (BMS), has conferred better outcomes for coronary artery stenting. [1][2][3][4] Although the administration of the first-generation DES showed a higher rate of success than that of the BMS, doubts were raised over its safety because of the reported cases of late stent thrombosis and very late restenosis. 5 The link between late stent thrombosis and incomplete endothelial coverage of the stent struts caused changes in the design and materials of the platforms and polymers of the stents. 6 Randomized controlled trials and studies have revealed promising results after the implantation of the zotarolimus-and the everolimus-eluting stents, in comparison with the first-generation DES and the BMS.7-9 On the other hand, concerns about late stent failure caused by untoward reactions to the stent polymer led to the introduction of a new-generation DES in which polymers degrade after the termination of drug release. 10 In these stents, drug release lasts about 28 days and an abluminal biodegradable polymer is absorbed after 6 to 9 months, thus turning the DES into a BMS and, theoretically, averting late stent failure as a result of reaction to polymers. Trials have shown the noninferiority of the biodegradable-polymer biolimus-eluting stent (BP-BES) to the previous generations of DESs; however, only a few investigators have compared the biodegradable-polymer with the durable-polymer DES in real-world registries. 11,12 Further analysis of large and

show abstract

“…Based on these excellent outcomes, it will be difficult to see any significant differences between BP-DES and EES. In a registry [48] including 814 patients with a median follow-up of 22 months, biolimus-eluting stents were similar to EES regarding safety (ST, MI or death) or efficacy (target vessel revascularization). In future clinical trials, more second-generation DES should be considered competitive comparators to corroborate the present finding.…”

Section: Possible Mechanisms Of Benefitmentioning

confidence: 99%

Impact of drug-eluting stents with different coating strategies on stent thrombosis: A meta-analysis of 19 randomized trials

et al. 2014

View full text Add to dashboard Cite

Background: Whether drug-eluting stents with biodegradable polymers (BP-DES) improve safety, especially with respect to stent thrombosis (ST) compared with permanent polymers DES (PP-DES (OR 0.33;) compared with PP-DES. There were no significant differences between the groups regarding MI incidence and mortality during both short and long follow-up periods. In stratified analyses, the long-term superiority of BP-DES was maintained only by using first-generation DES as the comparators. Conclusions: The present meta-analysis indicated that BP-DES were more efficacious than PP-DES at reducing the risks of very late ST and long-term TLR, but it could vary by heterogeneities in the use of PP-DES comparators. Additional rigorous RCTs with longer follow-upperiods are warranted to verify these very promising long-term endpoints. (Cardiol J 2014; 21, 5: 557-568)

show abstract

Long-term comparison of everolimus-eluting and biolimus-eluting stents

Abstract: This first clinical study failed to demonstrate any significant difference regarding safety or efficacy between these two types and generations of drug-eluting stents (DES).

Cited by 9 publications

References 23 publications

Favorable Vessel Healing After Nobori Biolimus A9-Eluting Stent Implantation

Favorable Vessel Healing After Nobori Biolimus A9-Eluting Stent Implantation

Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study

Impact of drug-eluting stents with different coating strategies on stent thrombosis: A meta-analysis of 19 randomized trials

Contact Info

Product

Resources

About